You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
Arch Venture Partners

BioCentury | Sep 09, 2020

Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...of four rounds of funding, Grail has named more than 25 of its participating investors; Arch Venture Partners...

BioCentury | Jul 23, 2021

Management Tracks

Borio adds public health, biodefense chops to Arch

...Resilience Inc., which is applying advanced manufacturing technologies to make biopharmaceutical supply chains more secure. Arch Venture Partners...
...addition to having served as an innovation fellow in R&D strategy at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Steve Usdin Arch Venture Partners U.S...

BioCentury | Jul 13, 2021

Emerging Company Profile

Prime Medicine: adding versatility to gene editing

...new investors join series A round backers Arch Venture Partners...
...of employees: About 50Funds raised: $315 millionInvestors: Arch Venture Partners...

BioCentury | Jul 13, 2021

BioCentury | Jun 23, 2021

Product Development

Treg start-ups — who, what and how much: Data Byte

...company Lyell Immunopharma Inc. (NASDAQ:LYEL) and Lyell investors Arch Venture Partners...

BioCentury | May 26, 2021

Finance

Building on discovery platform and early deals, CBC-backed NiKang adds $200M in crossover series C round

...round; a $50 million series B followed in September 2020.Privately held Erasca, whose backers include Arch Venture Partners...

BioCentury | May 19, 2021

Deals

May 19 Quick Takes: AI play Exscientia expands BMS collaboration; plus HiberCell, eureKARE and RWE Alliance

...Mount Sinai Innovation Partners and other undisclosed investors participated in the round alongside existing investors Arch Venture Partners...

BioCentury | May 13, 2021

Emerging Company Profile

Interline: correcting mutation-induced dysfunctional protein networks

...its platform to develop compounds that correct genetically driven dysfunction in protein networks.Foresite Capital and Arch Venture Partners...

BioCentury | May 13, 2021

BioCentury | May 11, 2021

Finance

May 10 Quick Takes: Novavax sinks on vaccine submission delay; plus Alebund, Gennao, Therini, Singular Genomics and more

...NASDAQ. The company, which has raised $69.5 million in venture funding, counts Deerfield Management and Arch Venture Partners...

BioCentury | Apr 29, 2021

Product Development

April 28 Quick Takes: Brukinsa data buoy BeiGene; plus Adverum, Dynamk, Pfizer-Amplyx, Boundless Bio and Clarus

...Wellington Management, Citadel’s Surveyor Capital, PFM Health Sciences and Logos Capital. Existing investors joining included Arch Venture Partners...

BioCentury | Apr 28, 2021

BioCentury | Apr 27, 2021

Product Development

Bilenker, Engelman launch Treeline with difficult-to-drug cancer targets as first focus

...Novartis Institutes for BioMedical Research global head oncology from June 2016 to the beginning of April.Arch Venture Partners...

BioCentury | Apr 17, 2021

Deals

April 16 Quick Takes: AZ’s $39B Alexion deal clears FTC hurdle; plus Biosplice, C2i, Relay, Surrozen and more

...in December with a $100 million series A round led by Lilly Asia Ventures and Arch Venture Partners...

BioCentury | Apr 14, 2021

Deals

April 13 Quick Takes: Mega-rounds for Flagship's Repertoire, Arcellx, GH, Theseus; plus Biophytis, Resilience, Cerevel, C4X, Sanofi and more

...upstream, downstream and aseptic fill finish in Ontario. Founded in 2020 by Robert Nelsen and Arch Venture Partners...

BioCentury | Apr 14, 2021

Emerging Company Profile

Jaguar to deploy $139M series B toward broad gene therapy pipeline

...therapy Zolgensma into gene therapies for broader indications.Arch Venture Partners...
...millionInvestors: Eli Lilly and Co. (NYSE:LLY), Deerfield, Arch Venture Partners, Goldman...

BioCentury | Apr 08, 2021

Finance

Venture rounds for Icosavax, Nucleix, Vizgen, Inscripta, Metagenomi and Volastra

...Tao Capital Partners, Pura Vida Investments and a large U.S. endowment fund and existing investors Arch Venture Partners...
...Catalio Capital Management joined the round along with existing investors including Polaris Partners, Droia Ventures, Arch Venture Partners...

BioCentury | Mar 31, 2021

Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

...Qatar Investment Authority, Redmile Group, 3B Future Health Fund (Helsinn Investment Fund), Canaan Partners and Arch Venture Partners.Outpace...

BioCentury | Mar 19, 2021

Deals

March 18 Quick Takes: SPAC Revolution, Idera, Translate tumble; plus Anima-Takeda, Boston-GSK, Accelmed, Gain IPO and more

...purchase a share at $11.50. The special purpose acquisition company’s sponsors are General Catalyst and Arch Venture Partners...

BioCentury | Mar 16, 2021

Deals

March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more

...Softbank Investment Advisors, Andreessen Horowitz, affiliates of T. Rowe Price, Casdin Capital, affiliates of BlackRock, Arch Venture Partners...

BioCentury | Mar 03, 2021

Deals

March 3 Quick Takes: Resilience acquires two manufacturing facilities in North America; plus Agilent-Resolution, AbbVie-Mitokinin, Fusion-Ipsen, LianBio-ReViral and Lava

...for upstream, downstream and aseptic fill finish in Ontario, Canada. Founded by Bob Nelsen and Arch Venture Partners...

BioCentury | Feb 25, 2021

Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...fellow new investor Boxer Capital of Tavistock Group. Versant co-led Vividion’s series A round with Arch Venture Partners...

BioCentury | Feb 19, 2021

Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...AAV technology from Dyno Therapeutics Inc. and Ally Therapeutics Inc., a stealthy newco backed by Arch Venture Partners...

BioCentury | Feb 17, 2021

Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...raised a $17 million venture round led by founding investor Longwood Fund, with participation from Arch Venture Partners...

BioCentury | Feb 04, 2021

Finance

Sana puts the pieces together, prices IPO that could soon be largest ever for a biotech

...Flagship Pioneering was Moderna’s largest shareholder, and with 21.4% before Sana’s offering, it’s second to Arch Venture Partners...

BioCentury | Feb 02, 2021

Finance

Sana among 10 biotechs set to flood market for IPOs

...has proposed the largest offering: cell and gene therapy company Sana Biotechnology Inc. Backed by Arch Venture Partners...

BioCentury | Jan 29, 2021

Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...filed for the IPO about two weeks ago, effected a 1-for-4 reverse stock split this week; Arch Venture Partners...
...Northpond Ventures and Deerfield Management joining first-time backers GV and Alexandria Venture Investments and returning investors Arch Venture Partners...

BioCentury | Jan 28, 2021

Finance

$1.9B fund gives Arch flexibility for more megarounds

...Director Paul Thurk passed away this month after more than 20 years with the firm. Paul Bonanos Arch Venture Partners...

BioCentury | Jan 23, 2021

Finance

2020’s most active biotech VCs: Data Byte

...of venture rounds of any series, and excludes venture debt.  Source: BioCentury’s BCIQ database Gunjan Ohri OrbiMed Advisors Arch Venture Partners RA...

BioCentury | Jan 23, 2021

Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...delivered in capsules or powder suspensions. In November, Arch Venture Partners...

BioCentury | Jan 22, 2021

Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...a venture partner at Lilly Asia Ventures. The firm co-led SciNeuro’s December series A round with Arch Venture Partners...
...LiUniversity collaborators: UndisclosedCorporate partners: UndisclosedNumber of employees: 10Funds raised: $100 millionInvestors: Lilly Asia Ventures Fund, Arch Venture Partners, ...

BioCentury | Jan 13, 2021

Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

...first INDs could be filed as soon as 2022. Backed by an investor syndicate led by Arch Venture Partners...

BioCentury | Jan 12, 2021

Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...company’s total funding to about $750 million.GV, Arch Venture Partners...

BioCentury | Dec 19, 2020

Politics, Policy & Law

COVID-19 mAb developers with ties to China excluded from Warp Speed

...and CEO of Brii, told BioCentury. Brii was launched in 2018 with $260 million from Arch Venture Partners...

BioCentury | Dec 16, 2020

Deals

Dec. 15 Quick Takes: Singlera raises $150M for cancer dx; plus AnGes-Emendo, Entresto, vTv and Unity

...David is stepping down as president of Unity Biotechnology Inc. (NASDAQ:UBX) while remaining on the board. Arch Venture Partners’...

BioCentury | Dec 15, 2020

Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...new investors RA Capital, Invus, Acuta Capital and SVB Leerink as well as existing investors Arch Venture Partners...
...affiliate of Elliott Management Corp. TARGETSTSLP – Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida Ventures RA Capital Management Invus Acuta Capital Partners SVB Leerink Arch Venture Partners Temasek Lightstone...

BioCentury | Dec 12, 2020

Management Tracks

Lum & Dipp’s Biospring rounds out team; plus CHOP’s Smith-Whitley joins GBT and updates from Orphazyme, Kronos, Dewpoint, Enanta and more

...January 2019 and raised $77 million in a September 2020 series B round led by Arch Venture Partners.Enanta...

BioCentury | Dec 11, 2020

Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

...in January 2019 and in September raised $77 million in a series B led by Arch Venture Partners.Faze’s...

BioCentury | Dec 10, 2020

Emerging Company Profile

Remix: targeting RNA modulating complexes

...validate targets in animal models. Both seed investors participated in the series A, as did Arch Venture Partners...
...Investments, Arch VenturePresident and CSO: Peter SmithPatents: None issued Danielle Golovin Atlas Venture The Column Group Foresite Capital Alexandria Venture Investments Arch Venture Partners...

BioCentury | Nov 25, 2020

Emerging Company Profile

Building Resilience into U.S. biomanufacturing

...including a $750 million series B led by Arch Venture Partners...
...employees: Over 300Funds raised: over $800 millionInvestors: Arch Venture Partners...

BioCentury | Oct 07, 2020

Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...in February 2019 with a $191 million venture round led by Third Rock Ventures and Arch Venture Partners.After...

BioCentury | Oct 01, 2020

Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

...Wednesday it has now raised a total of $70 million from investors including Lyell Immunopharma Inc., Arch Venture Partners...

BioCentury | Sep 29, 2020

Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

...of Akoya Biosciences Inc. Interim CEO Peidong Wang remains as VP of engineering. In January, Arch Venture Partners...

BioCentury | Sep 29, 2020

Finance

With $77M series B, condensates company Dewpoint aiming for proof of concept

...how condensates are implicated in disease states.To that end, Dewpoint Therapeutics has tapped round leader Arch Venture Partners...

BioCentury | Sep 22, 2020

Deals

Grail chooses Illumina takeout over IPO, promising more future returns for shareholders

...investors each, according to its prospectus. Behind Illumina, Arch Venture Partners...

BioCentury | Sep 19, 2020

Politics, Policy & Law

Biopharma companies, investors scrambling to work around WeChat ban

...said. Robert Nelsen, a managing director of Arch Venture Partners...

BioCentury | Sep 10, 2020

Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...by Lilly Asia Ventures to develop its single cell sequencing platform. New investors CDH investment, Arch Venture Partners...

BioCentury | Jul 23, 2021

Finance

July 22 Quick Takes: Anocca’s $47M B round to support Swedish biotech’s T cell pipeline

...the commercialization of its synthetic cell products, which include controls, diagnostics and adoptive cell therapies. Arch Venture Partners...

BioCentury | Aug 25, 2020

Management Tracks

Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more

...Development unit and was a member of the executive committee of Roche (SIX:ROG; OTCQX:RHHBY). In April, Arch Venture Partners...

BioCentury | Jul 23, 2020

Product Development

Encoded to drive first gene therapy into clinic with GV-led $135M series D

...too large for the vector. The financing drew participation from existing investors Matrix Capital Management, Arch Venture Partners...

BioCentury | Jul 15, 2020

Emerging Company Profile

Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

...Venture Partners, Waterman Ventures and Catalio Capital Management. Also participating were LS Polaris Innovation Fund, Arch Venture Partners...
...DNS Capital, New Leaf Venture Partners, Waterman Ventures, Catalio Capital Management, LS Polaris Innovation Fund, Arch Venture Partners...

BioCentury | Jul 09, 2020

Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

...inflammatory and autoimmune diseases company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Golumbeski is a partner at Arch Venture Partners...

BioCentury | Jul 07, 2020

Deals

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

...trial of metastatic TNBC patients. HiberCell launched last year with more than $60 million from Arch Venture Partners...

BioCentury | Jun 25, 2020

Emerging Company Profile

Sana’s quest to usher in next generation of cell, gene therapies

...announce the dollar amount until it had drawn down all of the money. Investors include Arch Venture Partners...
...Washington Corporate partners: None Number of employees: 230 Funds raised: More than $700 million Investors: Arch Venture Partners...

BioCentury | Jun 16, 2020

Product Development

Bit Bio scales up cell programming ambitions with $41.5M from blue-chip investors

...addition to former NCI director and serial cell therapy entrepreneur Klausner, Bit Bio’s investors include Arch Venture Partners...

BioCentury | Jun 11, 2020

Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

...existing shareholder GV decided it would rather lead the round itself. GV and existing investors Arch Venture Partners...

BioCentury | Jun 10, 2020

Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

...slated to enter the clinic next year, has a stronger genetic rationale than competing programs. Arch Venture Partners...
...University collaborators: OHSU Corporate partners: N/A Number of employees: 12 Funds raised: $94 million Investors: Arch Venture Partners...

BioCentury | Jun 10, 2020

Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...and Oriza Holdings as well as existing investors Loyal Valley Capital, Temasek, Sequoia Capital China, Arch Venture Partners...

BioCentury | May 26, 2020

Finance

insitro to translate $143 million B round into drug discovery platform

...Shanghai:603259) and other undisclosed investors joined Andreessen Horowitz in the oversubscribed B round. Existing investors Arch Venture Partners...

BioCentury | May 08, 2020

Finance

Daily Chart: this year’s most active life sciences VCs

Arch Venture Partners and RA Capital lead the pack among the most active life sciences VCs so far this year with nine investments each. Despite the pandemic, VCs are poised to invest, with no slowdown...

BioCentury | Apr 29, 2020

Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

...Therapeutics Inc. launched Monday with a $50 million series A round co-led by GV and Arch Venture Partners...
...Ting, Benjamin Greenbaum, Rosana Kapeller, Ari Nowacek, Bradley Backes, Jay Parrish in partnership with GV, Arch Venture Partners...
...of Alberta Corporate partners: N/A Number of employees: 10 Funds raised: $50 million Investors: GV, Arch Venture Partners...

BioCentury | Apr 28, 2020

Finance

Arch, Cormorant return to lead $200M megaround for Erasca

...pipeline toward the clinic, Erasca has raised one of the year’s two largest venture rounds. Arch Venture Partners...
...can do it all on our own would be wishful thinking.” Elizabeth S. Eaton, Staff Writer Erasca Inc. Arch Venture Partners Cormorant...

BioCentury | Apr 23, 2020

Finance

Venrock closes new evergreen fund at $447M

...at $450 million (see “Hustle and Fund” ). Qiming Venture Partners, Deerfield Management, venBio Partners, Arch Venture Partners...

BioCentury | Apr 06, 2020

Finance

Deerfield dives into emerging telemedicine tech with new $840M fund

...opportunities in telemedicine technologies are emerging from the crisis. The announcement comes four days after Arch Venture Partners...

BioCentury | Apr 04, 2020

Finance

Steady as venBio goes

...million. Returns can start to decrease as funds exceed $500 million, he said. On Thursday Arch Venture Partners...

BioCentury | Apr 02, 2020

Finance

Billion-dollar funds from Arch, Flagship show VCs are open for business

...Two of biotech’s most prominent company builders, Arch Venture Partners and Flagship Pioneering, unveiled new funds that raised...
...and sperm biology company Ohana Biosciences (see “Looking to the Other Half”) . Stephen Hansen, Associate Editor Arch Venture Partners Flagship...

BioCentury | Apr 01, 2020

Emerging Company Profile

Aspen plans to drive iPS cell therapy into Parkinson’s patients with $70M A round

...new indications with a $70 million series A round led by OrbiMed Advisors. Existing investors Arch Venture Partners...
...Corporate partners: None Number of employees: 33 Funds raised: $76.5 million Investors: Alexandria Venture Investments, Arch Venture Partners...
...Howard Federoff Patents: 1 issued Lauren Martz, Senior Editor Aspen Neuroscience Inc. OrbiMed Advisors Domain Associates LLC Section 32 Frazier Healthcare Partners Arch Venture Partners...

BioCentury | Mar 16, 2020

Politics, Policy & Law

Biotech CEOs respond to Sanders attack: science, not politics, will defeat the pandemic

...disease, not politics!” Biopharma executives and investors posted passionate defenses of the industry on Twitter. Arch Venture Partners’...
...to sign up for our daily email. Steve Usdin, Washington Editor Acorda Therapeutics Inc. Ovid Therapeutics Inc. Alnylam Pharmaceuticals Inc. Arch Venture Partners Biotechnology...

BioCentury | Feb 12, 2020

Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

...Oncology Ventures, the Global Health Sciences Fund from Quark Venture LP and GF Securities, and Arch Venture Partners...
...Oncology Ventures, the Global Health Sciences Fund from Quark Venture LP and GF Securities, and Arch Venture Partners...

BioCentury | Feb 07, 2020

Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

...Treg-based cell therapies for autoimmune and neurodegenerative diseases. Sonoma’s investor syndicate includes Lyell Immunopharma Inc., Arch Venture Partners...
...Corporate partners: Lyell Immunopharma Inc. Number of employees: 11 Funds raised: $40 million Investors: Lyell, Arch Venture Partners...

BioCentury | Feb 06, 2020

Finance

Schrödinger, Beam are latest to post gains after pricing larger-than-expected IPOs

...Beam’s pipeline spans oncology, hematology, liver disorders, ophthalmology and CNS conditions. Its top shareholders include Arch Venture Partners...

BioCentury | Jan 30, 2020

Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

...NASDAQ:AMGN) acquired in 2012. Crandell and Walt both serve on Vizgen's board. Elizabeth S. Eaton, Staff Writer Arch Venture Partners Vizgen transcriptome RNA imaging...

BioCentury | Jan 12, 2020

Emerging Company Profile

Borisy newco aims to offer ‘radically’ cheaper drugs by disrupting biopharma’s traditional model

...the near future. EQRx Inc. debuted with $200 million in series A funding from GV, Arch Venture Partners...

BioCentury | Jan 10, 2020

Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...$60 million in a series C round led by Madrone Capital Partners with participation by Arch Venture Partners...

BioCentury | Jan 09, 2020

Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...existing investors Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China and ARCH Venture Partners...

BioCentury | Dec 18, 2019

Financial News

With new name, Epirium snags $85M series A to develop hormonal therapy for muscular dystrophies

...as Epirium Bio with a tranched $85 million series A led by Longitude Capital and Arch Venture Partners...

BioCentury | Dec 13, 2019

Finance

Aspen’s debut reveals first cell therapy investment by Domain

...a series A in 2020, but declined to disclose a fund-raising target. Alexandria Venture Investments, Arch Venture Partners...

BioCentury | Nov 21, 2019

Company News

Brii continues to grow infectious disease pipeline via deal with start-up AN2

...global companies to develop in China. The company launched in 2018 with $260 million from Arch Venture Partners...

BioCentury | Nov 19, 2019

Politics & Policy

Investors sound alarm about pending drug pricing legislation

...not identify such policies. The letter was signed by: Robert Nelson, co-founder & managing director, Arch Venture Partners...

BioCentury | Nov 18, 2019

Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

...an August regulatory filing. PureTech gained 30p (14%) to 249p on Monday. Other shareholders included Arch Venture Partners...

BioCentury | Nov 08, 2019

Financial News

eGenesis pushes to bring pig organ transplants to humans with $100M series B

...which contributed $50 million -- and Wellington Partners also participated, as did existing investors including Arch Venture Partners...

BioCentury | Oct 17, 2019

Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

...treat solid malignancies. Carrick raised $95 million in a 2016 series A round led by Arch Venture Partners...

BioCentury | Oct 11, 2019

Financial News

Vir’s aftermarket weakness adds to skittishness for IPO queue

...company across its three-and-a-half-year life span. Figures in its prospectus suggest that its original investor, Arch Venture Partners...

BioCentury | Oct 09, 2019

Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

...Pharma Inc., where she helped develop CAR T therapy Yescarta axicabtagene ciloleucel. Lyell’s board includes Arch Venture Partners’...

BioCentury | Sep 27, 2019

Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

...hematology, oncology, liver, ocular and CNS diseases and expects to begin submitting INDs in 2021. Arch Venture Partners...

BioCentury | Sep 20, 2019

Emerging Company Profile

Boundless Bio: designing cancer therapies around extrachromosomal DNA

...With a $46.4 million series A round led by Arch Venture Partners and City Hill Ventures, Boundless Bio...

BioCentury | Sep 04, 2019

Financial News

Vir plots IPO as more programs near clinic

...vaccine against tuberculosis. Vir had $356.5 million in cash at June 30. Top shareholders include Arch Venture Partners...

BioCentury | Aug 07, 2019

Company News

Management tracks: Gilead's McHutchison joins Assembly as CEO; plus Lilly, Vor, HiberCell, insitro and more

...Gillis chairman and named Colin Goddard to the board. Gillis is a managing director of Arch Venture Partners...

BioCentury | Jul 26, 2019

Product Development

Institute for Protein Design's de novo revolution

...Inc. and Grail Inc. and formerly directed NIH's National Cancer Institute (NCI). Lyell's board includes Arch Venture Partners'...

BioCentury | Jul 12, 2019

Financial News

July 11 Financial Quick Takes: Illumina tumbles on revenue miss; plus PureTech, Horizon and more

...Pte. Ltd. (Singapore) raised $5 million in a series A led by BioPath Ventures and Arch Venture Partners...
...a sample preparation device to purify and isolate nucleic acids. BioCentury Staff Agency for Science Technology and Research Arch Venture Partners Horizon...

BioCentury | Jun 27, 2019

Company News

With $104M series C debut, Encoded takes on expansion of gene therapies

...of clinical trials. The series C syndicate comprised all the company’s existing investors -- Venrock, Arch Venture Partners...
...collaborators: N/A Corporate partners: N/A Number of employees: 50 Funds raised: $158 million Investors: Venrock, Arch Venture Partners...

BioCentury | Jun 13, 2019

Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

...HC participated in the round alongside existing investors Alexandria Venture Investments, Altitude Life Science Ventures, Arch Venture Partners...

BioCentury | Jun 07, 2019

Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

...for 44 life science companies -- over 50% more than the next most active VC, Arch Venture Partners...
...supported by an advisory board that includes executives from AbbVie Inc., Accelerator Life Science Partners, Arch Venture Partners...
...revenue (see Figure: Alexandria's Syndicates). Figure: Alexandria’s syndicates Alexandria Venture Investments’ most frequent co-investor is Arch Venture Partners...

BioCentury | Jun 07, 2019

Emerging Company Profile

insitro: machine learning with designated data

...Sciences Inc. Number of employees: 37 Funds raised: Over $100 million Investors: Andreessen Horowitz (a16z), Arch Venture Partners...

BioCentury | May 31, 2019

Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

...the corporate venture fund of WuXi AppTec Co. Ltd., as well as Alexandria Venture Investments, Arch Venture Partners...

BioCentury | May 23, 2019

Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

...platform enabled Locana to attract $55 million in series A funding led by existing investor Arch Venture Partners...
...Cayce Denton and Lightstone’s Jean George. UCB’s Emmanuel Lacroix is a board observer. Chris Lieu, Staff Writer Arch Venture Partners Locanabio...

BioCentury | May 20, 2019

Company News

May 20 Company Quick Takes: LifeArc trades Keytruda royalties for $1.3B; plus Evotec-Just, Actelion-Owlstone, Genomind

...small molecules through its acquisition of Just Biotherapeutics Inc. (Seattle, Wash.). Just Biotherapeutics equity holders Arch Venture Partners...